Elmiron Lawsuits Filed for Patients with Vision Loss Due to Elmiron Use
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are handling Elmiron lawsuits for patients who have suffered vision loss due to their use of Elmiron. These Elmiron lawsuits are filed against the drug companies responsible for Elmiron. This is because — despite a growing number of Elmiron-related vision loss case reports in the medical literature over the past few years — it was not until June 2020 that any warning about eye problems was included in the Elmiron drug label here in the US.
This Elmiron label change in June 2020 finally added some warnings for serious eye problems such as retinal pigmentary changes and pigmentary maculopathy. From our perspective, these warnings about Elmiron eye side effects were long overdue.
We are currently investigating possible Elmiron lawsuits for patients diagnosed with eye problems such as:
- Vision Loss / Blindness
- Maculopathy (retinal or pigmentation)
- Retinal Pigmentary Endothelium Injury (RPE)
- Pigmentation Maculitis
- Macular Degeneration (pigmentation or dry)
It is important to know that our Elmiron lawsuits for patients who have suffered vision loss are filed only against the pharmaceutical companies responsible for Elmiron — not the doctors who prescribed the Elmiron as a treatment for their bladder diseases.
Significantly, it is not necessary for the patient to have been using Elmiron regularly right up until the time when their Elmiron-related vision loss was diagnosed in order to file an Elmiron lawsuit. That is, unlike most other drug injury cases, the patient could have stopped using Elmiron months before a medical doctor was able to diagnose their eye problem.
Please feel free to contact us if we can be of assistance to you in regards to a possible Elmiron lawsuit.
Free Elmiron Case Evaluation
We encourage you to submit an Elmiron Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, nor some other lawyer – about your case based on his many years of experience.
Most Recent Article About Elmiron
A 2021 Look at the Increased Risk of Elmiron-associated Pigmentary Maculopathy
We have reported previously on Elmiron-related eye damage, particularly that long-term use of the interstitial cystitis treatment drug Elmiron has been linked to maculopathy eye damage. In this post, we present a 2021 Elmiron medical journal article wherein it is estimated that around 20% of interstitial cystitis patients with long-term Elmiron use may eventually be diagnosed with Elmiron-associated pigmentary maculopathy.
In the March 2021 edition of Current Opinion in Ophthalmology, a medical journal article elaborated on the degree of increased risk of Elmiron-associated pigmentary maculopathy. Here is the Abstract for “Update on maculopathy secondary to pentosan polysulfate toxicity” which provides some important details:
To read more of this article, click below:
Purpose of review: The aim of the present review is to provide a comprehensive summary of available knowledge regarding toxic maculopathy secondary to [Elmiron, or pentosan polysulfate sodium (PPS)].
Recent findings: [Elmiron (PPS) toxicity] was described in 2018, and additional studies characterize it as dysfunction of the retinal pigment epithelium centered on the posterior pole, which can progress despite drug cessation. Requisite exposure can be as little as 0.325 kg and 2.25 years but averages closer to 1–2 kg and 10–15 years. Multimodal imaging should include near-infrared reflectance, optical coherence tomography, and fundus autofluorescence. Cross-sectional studies demonstrate evidence correlating cumulative dosing and the likelihood/severity of maculopathy. Early estimates of prevalence range from 12.7 to 41.7% depending on dosing, with overall rates around 20%.
It is important to know that a patient does not need to have current Elmiron use right up until the time when their pigmentary maculopathy is diagnosed for it to be considered Elmiron-related eye damage.
We are currently investigating possible Elmiron lawsuits for patients with past Elmiron use diagnosed with pigmentary maculopathy. If we can assist you with an Elmiron-related eye damage legal case, you can submit an online Elmiron Case Evaluation Form or call us on our toll-free number: 800-426-9535.
[Read article in full at original source]Our earlier articles about Elmiron:
- New Elmiron Medication Guide Points Out Retinal Pigmentary Eye Problems
- Elmiron Can Double the Risk of Pigmentary Maculopathy or Macular Degeneration
- Maculopathy Patients Should be Asked About Any Elmiron Use in Past
- Elmiron Legal Cases for Eye Damage and Retinal Injury Are Consolidated in Elmiron MDL
- Elmiron Updates: Legal, Medical, and Regulatory – December 2020
- Are Elmiron Side Effects Risks for Eye and Vision Are Greater Than Its Bladder Treatment Benefits?
- Elmiron Lawsuits Being Filed Against Drug Companies for Elmiron-Related Eye Problems
- FDA Announces Elmiron Drug Safety-Related Labeling Changes
- Elmiron Potentially Linked to Severe Eye Disorders